Interleukin (IL)-6 appears to be a biomarker for distant recurrence in patients treated for stage II to III, HER2-negative early breast cancer, according to a case-control study of patients in the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E5103 trial.
The aim of the case-control study was to evaluate the association between serum samples and inflammatory cytokines and chemokines in distant recurrence of breast cancer. Patients had stage II to III,